Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 19, 2018
Pharmacy Choice - Pharmaceutical News - ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise Ultrasound Denervation System For Treatment Of Hypertension - August 19, 2018

Pharmacy News Article

 7/22/18 - ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise Ultrasound Denervation System For Treatment Of Hypertension

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA ReCor Medical announced that the US Food & Drug Administration approved the Company's new pivotal study of the Paradise Ultrasound Denervation System for the treatment of hypertension: RADIANCE-II (see also ReCor Medical Inc.).

Building upon the recent positive results of the Company's RADIANCE-HTN SOLO study, RADIANCE-II will be a randomized, sham-controlled, blinded study in patients with moderate hypertension, powered to demonstrate the safety and efficacy of the Paradise System's ability to lower blood pressure. ReCor expects to initiate enrollment in RADIANCE-II in October of this year.

"We have had a very constructive dialog with the FDA during the past 9 months to craft what we believe is a strong study to develop a robust set of clinical data to support the future FDA review for PMA approval," commented Leslie Coleman, Vice President of Regulatory & Medical Affairs. "At the time of PMA submission we plan to have 4 independently-powered, blinded, sham-controlled, randomized studies of the Paradise System in patients with different stages of hypertension - our SOLO, TRIO, REQUIRE, and RADIANCE-II studies - approaching a total of nearly 500 subjects, with outcomes as long as 3 years."

"Our Steering Committee and medical advisors have been instrumental in the design of the Global RADIANCE Clinical Program - including the RADIANCE-II pivotal study - for the US, Europe, Japan and Korea," added Helen Reeve-Stoffer, Vice President of Clinical Affairs. "Given the recent positive SOLO results, and subsequently the numerous review articles in medical journals, we recognize the potential impact the Paradise System may have in the treatment of hypertension for millions of patients world-wide. Accordingly, ReCor is committed to conduct rigorous, randomized, controlled studies to demonstrate the safety and efficacy of the Paradise System to lower blood pressure, thus helping physicians to evaluate how, in whom, and when to use Paradise for the treatment of hypertension."

Keywords for this news article include: Business, FDA Actions, Hypertension, ReCor Medical Inc, Health and Medicine, Cardiovascular Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Aug 19: Stress to Adrenal Fatigue
Last Chance
Aug 20: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Aug 21: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Aug 22: Pharmacy & the Opioid Crisis
Aug 23: Medication Use During Pregnancy & Lactation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement